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OBJECTIVE — TheaimofthisstudywastoexaminetheeffectofproteinkinaseCinhibition
with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte che-
moattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system
blockade-treated type 1 diabetic subjects.
RESEARCH DESIGN AND METHODS — Albuminuric subjects were randomized
(2:1)toruboxistaurin(32mgdaily;n13)orplacebo(n7)for8weeks.Renalhemodynamic
function was measured during clamped euglycemia or hyperglycemia and before and after
ruboxistaurin or placebo.
RESULTS — Ruboxistaurin was not associated with between-group differences during
clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperﬁlterers with
normoﬁlterers during euglycemia, glomerular ﬁltration rate and MCP-1 decreased, whereas the
epidermal growth factor–to–MCP-1 ratio increased in hyperﬁlterers versus normoﬁlterers (all
P  0.05).
CONCLUSIONS — The effect of ruboxistaurin is modest and dependent, at least in part, on
the level of ambient glycemia and baseline glomerular ﬁltration rate.
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xperimental studies of diabetes have
suggested that the activation of the
intracellular signaling molecule pro-
tein kinase C (PKC) is associated with
renal hyperﬁltration and development of
diabetes complications (1,2). PKC acti-
vation in diabetes is associated with loss
of key protective trophic factors, such as
epidermal growth factor (EGF) (3), and
with expression of proinﬂammatory me-
diators such as monocyte chemoattrac-
tantprotein-1(MCP-1)(4,5).Muchlessis
known about the role of PKC activation
in the pathogenesis of renal hemody-
namicandmolecularabnormalitiesinhu-
man diabetes.
Accordingly, in this pilot study, we
hypothesized that ruboxistaurin would
reversethehemodynamiceffectsofdiabe-
tesandblunttheresponsetoclampedhy-
perglycemia. In a post hoc analysis, we
analyzed subjects on the basis of the pres-
ence of renal hyperﬁltration during
clampedeuglycemia(6,7).Wealsoexam-
ined the effect of ruboxistaurin on the ex-
cretion of the urinary biomarkers MCP-1
and EGF (4,8,9).
RESEARCH DESIGN AND
METHODS— After giving informed
consent, subjects (Table A1, with inclu-
sion/exclusion criteria, is available in an
online appendix at http://dx.doi.org/10.
2337/dc08-1609) adhered to a diet that
was Na replete and moderate in protein
for 7 days before each experiment (6,7).
Euglycemic (blood glucose 4–6 mmol/l)
and hyperglycemic (blood glucose 9–11
mmol/l) conditions were maintained on
two consecutive days using a modiﬁed
glucose clamp technique, and renal he-
modynamicfunctionwasmeasuredusing
inulin and para-aminohippurate (6,7).
Urinary biomarkers were measured by
ELISA (Quantikine; R&D Systems, Min-
neapolis, MN) before and after treatment
with ruboxistaurin or placebo, normal-
ized for urinary creatinine. Subjects were
then randomized (2:1) to ruboxistaurin
(32 mg daily for 8 weeks) or a placebo in
a double-blind fashion. All subjects were
taking an ACE inhibitor, an angiotensin
receptor blocker (ARB), or a combination
throughout the study. The University
Health Network Research Ethics Board
approved the protocol.
The primary analysis examined he-
modynamic responses during clamped
euglycemia and hyperglycemia before
and after treatment with ruboxistaurin or
the placebo. In a post hoc analysis, we
analyzed subjects on the basis of ﬁltration
status (hyperﬁltration, glomerular ﬁltra-
tion rate [GFR] 135 ml/min per 1.73
m
2; normoﬁltration, 135 ml/min per
1.73 m
2) (6,7). Between-group compari-
sons of all parameters at baseline were
made using parametric methods (un-
paired Student’s t test). Within-subject
and between-group differences in the re-
sponse to PKC inhibition were deter-
minedbyrepeated-measuresANOVA.All
statistical analyses were performed using
SPSS (version 14; SPSS, Chicago, IL).
RESULTS— Baseline clinical charac-
teristicsareshowninonlineappendixTa-
ble A2. At baseline, mean  SEM arterial
pressure was higher in the ruboxistaurin
group (96  1 mmHg) than in the pla-
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clampedeuglycemia.Intheprimaryanal-
ysis, during clamped euglycemia,
ruboxistaurin was associated with a re-
duction in mean arterial pressure (96  1
to 91  2 mmHg; P  0.032) but did not
inﬂuence renal hemodynamic function.
During clamped hyperglycemia (online
appendix Table A3), ruboxistaurin was
associated with declines in effective renal
plasma ﬂow (ERPF) and renal blood ﬂow
and a rise in ﬁltration fraction (all P 
0.05). Ruboxistaurin did not change
MCP-1,EGF,ortheEGF–to–MCP-1ratio
in urinary excretion.
When analyzed on the basis of ﬁltra-
tion status, hyperﬁltration (n  4) and
normoﬁltration (n  9) subjects were
similar at baseline (data not shown). In
hyperﬁltration subjects, ruboxistaurin
was associated with a decline in GFR that
was signiﬁcant compared with the re-
sponse in normoﬁltration subjects (Fig.
1). When analyzed on the basis of ﬁltra-
tion status, ruboxistaurin was associated
withadecreaseinMCP-1(P0.041)and
a rise in the EGF–to–MCP-1 ratio (P 
0.041) in hyperﬁltration versus normoﬁl-
tration subjects (online appendix Figures
A1–A3).
CONCLUSIONS — The aim of this
study was to determine the role of PKC
inhibition in humans with diabetes. Our
major ﬁndings were that 1) during
clamped hyperglycemia, ruboxistaurin
lowered ERPF and renal blood ﬂow, and
2)inaposthocanalysisbasedonﬁltration
status, ruboxistaurin partially corrected
hyperﬁltration during clamped euglyce-
mia, while MCP-1 decreased and the
EGF–to–MCP-1 ratio increased in hyper-
ﬁltration versus normoﬁltration subjects.
Renal hemodynamic complications,
including hyperﬁltration, occur early in
the natural history of diabetes and may in
part be due to a hyperglycemia-mediated
increase in PKC activity (1). Our ﬁrst
major ﬁnding was that during clamped
euglycemia, ruboxistaurin did not signif-
icantly affect renal hemodynamic function.
In contrast, during clamped hyperglyce-
mia, ruboxistaurin lowered ERPF but
there was no effect on GFR. Although
from this experiment we could not deter-
mine why ruboxistaurin failed to lower
GFR during hyperglycemia, the explana-
tion may involve activation of redundant
hemodynamic pathways, such as endo-
thelin or cyclooxygenase-2, leading to the
maintenance of GFR (10,11).
We have previously reported that
baseline GFR during clamped euglycemia
is a determinant of renal hemodynamic
responsiveness (6). Our second major
ﬁnding was that ruboxistaurin was asso-
ciated with reductions in GFR and ﬁltra-
tion fraction without affecting ERPF in
hyperﬁltration subjects but was not asso-
ciated with such reductions in normoﬁl-
tration subjects. Furthermore, the change
in the urinary biomarkers in hyperﬁltra-
tion subjects was consistent with protec-
tion against renal injury (a decline in
MCP-1 and a rise in the EGF–to–MCP-1
ratio) (12). Although we cannot deter-
mine the precise pathway responsible for
these hemodynamic and molecular ef-
fects, we favor the theory that rubox-
istaurin may have inhibited the effects of
angiotensin II, leading to vasodilatation
and a fall in GFR. The responsible mech-
anisms for these observations require fur-
ther investigation in animal studies
because these parameters cannot be as-
sessed in humans.
This study has important limitations.
We attempted to minimize the effect of
the small sample size with homogeneous
study groups, careful prestudy dietary
preparation, and a study design that al-
lowedeachsubjecttoactashisorherown
control. We were also prevented from
studyingtheindependenteffectofrubox-
istaurinbecauseofethicalconcernsabout
discontinuing ACE inhibitor or ARB ther-
apy in this proteinuric cohort of subjects.
Therefore,theeffectofruboxistaurinmay
have been blunted by a preexisting renin
angiotensin system blockade.
In conclusion, PKC appears to play
a role in the maintenance of hyperﬁltra-
tion in patients with type 1 diabetes, and
its inhibition results in a decrease in GFR
and proinﬂammatory urinary biomark-
ers.TheroleofPKCmaybeenhancedin
hyperﬁltration patients, suggesting that
the impact of ruboxistaurin depends on
ﬁltration status.
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